Hi {{lead.First Name:default=edit me}},

You know that human biospecimens represent the best research model, but accessing the right human samples can be challenging. Fortunately, Genentech's pipeline matches well with Sanguine’s network of highly characterized and recallable patient donors, so your team can set forth inclusion/exclusion criteria, obtain patient reported outcome data, and receive samples and leukopaks in a timely manner. Sanguine's nationwide donor network includes (search the database)

  • > 25,000 donors with autoimmune indications, our most diverse patient group
  • > 10,000 donors for respiratory & metabolic research
  • > 5,000 donors with infectious diseases

Genentech's commitment to treating these conditions and Sanguine's goal of connecting patients to researchers explains why our companies have partnered on over 10 studies. Let’s discuss whether we can continue succeeding for patients.

Warm Regards,

Lisl Mayer
Research Consultant
Sanguine Bio | Massachusetts

Schedule a Meeting
| www.sanguinebio.com